SCHEMBL10283262

SCHEMBL10283262

O=C(O)c1ccc2c(C3CCCCC3)c3n(c2c1)CCN(CC(=O)N1CCOCC1)c1ccccc1-3

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.48
MMP12 P39900 1/20 0.48
NR1I2 O75469 1/20 0.46
SCN9A Q15858 3/20 0.40
KMT2A Q03164 4/20 0.38
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 3/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
GAA P10253 2/20 0.38
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38
ALOX12 P18054 1/20 0.38
MAPK1 P28482 1/20 0.38
ATM Q13315 1/20 0.38
CCKBR P32239 1/20 0.38
CHRM2 P08172 2/20 0.36
CHRM4 P08173 2/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL803809 0.98 PRKCA (0.46) PRKCAMMP12NR1I2SCN9AKMT2A
SCHEMBL12427628 0.93 PRKCA (0.48) PRKCAMMP12NR1I2SCN9AKMT2A
SCHEMBL804590 0.93 PRKCA (0.48) PRKCAMMP12NR1I2SCN9AKMT2A
SCHEMBL10283570 0.93 PRKCA (0.48) PRKCAMMP12NR1I2SCN9AKMT2A
SCHEMBL10283571 0.93 PRKCA (0.48) PRKCAMMP12NR1I2SCN9AKMT2A
SCHEMBL804154 0.93 PRKCA (0.48) PRKCAMMP12NR1I2SCN9AKMT2A
SCHEMBL804718 0.91 PRKCA (0.45) PRKCAMMP12NR1I2SCN9AKMT2A
SCHEMBL12427575 0.91 PRKCA (0.48) PRKCAMMP12NR1I2SCN9AKMT2A
SCHEMBL10283490 0.90 NR1I2 (0.46) PRKCAMMP12NR1I2SCN9AKMT2A
SCHEMBL12427618 0.90 PRKCA (0.49) PRKCAMMP12NR1I2SCN9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 PRKCA 2404/4885MMP12 1013/4885NR1I2 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.